Catapres 100microgram tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Clonidine hydrochloride

Available from:

Glenwood GmbH

ATC code:

C02AC01

INN (International Name):

Clonidine hydrochloride

Dosage:

100microgram

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02050200; GTIN: 5012816025660

Patient Information leaflet

315900-009
PACKAGE LEAFLET: INFORMATION FOR THE USER
READ ALL OF THIS LEAFLET CAREFULLY BEFORE
YOU START TAKING THIS MEDICINE.
• Keep this leaflet. You may need to read
it again.
• If you have any further questions, ask
your doctor or pharmacist.
• This medicine has been prescribed for
you. Do not pass it on to others. It may
harm them, even if their symptoms are
the same as yours.
• If any of the side effects gets
troublesome or serious, or if you
notice any side effects not listed in this
leaflet, please tell your doctor or
pharmacist.
IN THIS LEAFLET:
1. What CATAPRES Tablets are and what
they are used for
2. Before you take CATAPRES Tablets
3. How to take CATAPRES Tablets
4. Possible side effects
5. How to store CATAPRES Tablets
6. Further information
1. WHAT CATAPRES TABLETS ARE AND
WHAT THEY ARE USED FOR
CATAPRES Tablets contain a medicine
called clonidine. This belongs to a group
of medicines called antihypertensives.
CATAPRES is used to lower high blood
pressure (to treat hypertension).
2. BEFORE YOU TAKE CATAPRES TABLETS
DO NOT TAKE CATAPRES IF:
• You are pregnant, likely to get pregnant
or are breast-feeding
• You are allergic (hypersensitive) to
clonidine or any of the other
ingredients of CATAPRES (see section
6: Further information)
• You have a slow heart rate due to heart
problems
Do not take this medicine if any of the
above apply to you. If you are not sure,
talk to your doctor or pharmacist before
using CATAPRES.
TAKE SPECIAL CARE WITH CATAPRES
Check with your doctor or pharmacist
before taking CATAPRES if:
• You have Raynaud’s disease (a problem
with circulation to the fingers and toes)
or other blood circulation problems,
including circulation to the brain
• You have heart or kidney problems
• You have or have ever had depression
• You have constipation
• You have a nerve disorder that causes
your hands and feet to feel different
(‘altered sensation’) or low blood
pressure when you stand up
If you are not sure if any of the above
apply to you, talk to your doctor

Summary of Product characteristics

OBJECT 1
CATAPRES TABLETS 100MCG
Summary of Product Characteristics Updated 12-Aug-2014 | Boehringer
Ingelheim Limited
1. Name of the medicinal product
Catapres Tablets 100 micrograms
2. Qualitative and quantitative composition
Each tablet contains 100 micrograms of clonidine hydrochloride.
For excipients see 6.1
3. Pharmaceutical form
Tablet
White, circular, flat, bevel-edged tablets impressed with the
identifying code
on one side and
the company symbol on the reverse.
4. Clinical particulars
4.1 Therapeutic indications
Catapres is indicated for the treatment of all grades of essential and
secondary hypertension.
4.2 Posology and method of administration
Catapres Tablets are for oral administration only.
Adults:
Oral treatment should commence with 50 - 100 micrograms three times
daily. This dose should be
increased gradually every second or third day until control is
achieved. Most patients will be controlled
on divided daily doses of 300 - 1200 micrograms. However, some
patients may require higher doses, e.g.
1800 micrograms or more.
Catapres may be added to an existing antihypertensive regimen where
blood pressure control has not been
satisfactorily achieved. If side-effects with existing therapy are
troublesome the concomitant use of
Catapres may allow a lower dose of the established regimen to be
employed. Patients changing treatment
should have their existing therapy reduced gradually whilst Catapres
is added to their regimen.
Patients undergoing anaesthesia should continue their Catapres
treatment before, during and after
anaesthesia using oral or i.v. administration according to individual
circumstances.
No specific information on the use of this product in the elderly is
available. Clinical trials have included
patients over 65 years and no adverse reactions specific to this age
group have been reported.
_PAEDIATRIC POPULATION:_
There is insufficient evidence for the application of clonidine in
children and adolescents younger than 18
years. Therefore the use of clonidine is not recommended in paediatric